Microsoft has ended support for its pre-IE11 browsers as of January 2016 and will be discontinuing IE11 support in August 2021.

If you are seeing this message, you are viewing the site on one of these unsupported browsers. We only support the recent versions of major browsers such as Chrome, Firefox, Safari, and Edge.

Thank you.

(click to close and continue using this browser)

Sign InDues Join Donate Privacy Contact Search
Home News APCR Comment Opposing H.R. 3


APCR Comment Opposing H.R. 3

posted: August 31, 2021

Washington, DC — The Academy of Physicians in Clinical Research (APCR) issued the following statement urging Congress to not include H.R. 3 or other similar proposals in the upcoming reconciliation package:

We are deeply concerned to hear that House Democrats are considering including a bill like H.R.3, or similar policies, in the upcoming reconciliation package. As has been widely reported by the Congressional Budget Office and academics, H.R. 3 would lead to the loss of over 50 new medicines, and we have no ideas which ones. Will it halt the development of new platform technologies that could lead to the vaccine against a future pandemic? Where would we be today if H.R. 3 had been in effect over the last decade? Progress against COVID-19, cancer, or other hard to treat conditions may have been out of reach.

As physician researchers who design and run the clinical trials that lead to the development of new medicines, we are deeply concerned that Congress would be focused on making us less and not more prepared for future pandemics and other threats to patient health.

H.R. 3 mimics the tactics used in other countries where access to cutting edge medicines is significantly stymied. Prioritizing other initiatives over access to these medicines for American patients is not sound public policy.

We strongly urge you to oppose including H.R. 3 or other similar proposals in the mark-up of the upcoming reconciliation package.